Our experimental monoclonal antibody, Xentuzumab – formerly referred to as BI 836845 – represents a significant effort by Astellas Inc. targeting PD-1. The development initially focused on solid tumor treatments, https://dawudfdfm039313.aboutyoublog.com/54125057/xentuzumab-a-deep-analysis-into-bi-836845-and-its-evolution